

Cantourage Group SE

Health Care / Pharma - Germany



Buy (old: Buy)

06.09.2023

EUR 12.50 (old: EUR 12.00)

Own telemedicine platform to ease prescription hurdles; chg.

Despite medical cannabis being approved for therapeutical purposes since 2017, adoption rates are still low. To some extent, this is the result of the complex prescription processes that potential patients have to go through.

With the **launch of its own telemedicine platform, telecan°**, Cantourage is planning to change that. In detail, telecan° is connecting potential patients with doctors that offer personalized therapies based on medical cannabis, while at the same time handling the necessary appointment and billing management, trainings and other backoffice tasks. Further, issued prescriptions are directly sent to a pharmacy with the necessary product in stock, which is essential as availability of strains can strongly vary, resulting in significantly shorter waiting times for patients.

While we don't expect any significant financial contributions from the platform by itself (eNuW: € 100 for first ~30 minute consultancy session and initial prescription, € 20 for follow on prescriptions), it, coupled with educational/awareness initiatives e.g. together with Purize, **should allow Cantourage to take an active role in developing the medical cannabis market.**

The planned **de-classification of cannabis as a narcotic drug** (BtM) should further accelerate this trend. Once the "Cannabis Act" becomes effective (eNuW: early 2024e), Germany will not only allow adults to own 25 grams of cannabis, grow up to three plants and establish non-profit cannabis clubs but cannabis will also lose its narcotic drug status. As a result, getting a prescription for cannabis should become as easy as getting one for ibuprofen 600. Through this, medical cannabis could also become part and benefit from the German e-script universe, which just launched in July this year.


What's more, Cantourage is executing on the targeted ramp-up. The company has signed long-term agreements with more than 60 grower partners and is expanding its dronabinol footprint across Europe through a cooperation with a leading pharmaceutical wholesaler in Austria. As a result, the company is seen to strongly grow its top-line (eNuW: 71% CAGR 2022-25e) while already achieving EBITDA break-even in FY23e.

We reiterate our **BUY rating with a new € 12.5** (old: € 12), based on DCF.

Y/E 31.12 (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	0.5	5.2	14.2	30.7	57.1	72.6
Sales growth	n.a.	884.2%	171.7%	116.8%	85.7%	27.2%
EBITDA	-0.6	-0.8	-2.0	0.6	3.6	7.0
Net debt (if net cash=0)	2.6	2.6	2.6	2.6	-2.7	-5.5
FCF	-1.2	-2.0	-3.3	-0.1	0.6	2.7
Net Debt/EBITDA	-4.7	-3.2	-1.3	4.1	0.0	0.0
EPS pro forma	-0.05	-0.08	-0.18	0.01	0.16	0.33
EBITDA margin	-104.7%	-15.8%	-14.1%	2.1%	6.3%	9.6%
ROCE	-44.4%	-14.0%	-17.9%	1.3%	19.1%	33.8%
EV/sales	240.6	24.4	14.4	4.1	2.1	1.6
EV/EBITDA	-229.8	-154.8	-102.1	198.9	33.7	17.1
PER	-212.8	-129.1	-54.6	692.8	64.5	30.2
Adjusted FCF yield	-0.5%	-0.8%	-1.1%	0.1%	1.6%	3.5%


Source: Company data, NuWays, Close price as of 05.09.2023

Sales (2020-25e)




Source: NuWays Research

EBIT margin (2020-25e)



Source: NuWays Research


ROCE (2020-25e)



Source: NuWays Research

Company description

Cantourage wants to revolutionize the German medical cannabis market for the benefit of patients. It enables cultivators from around the world to offer their products in Europe, one of the fastest growing cannabis markets in the world.



Market data

Share price (in €)	10.02
Market cap (in € m)	124.9
Number of shares (in m pcs)	12.5
Enterprise value (in € m)	127.5
Ø trading volume (6 months)	5,080

Identifier

Bloomberg	HIGH GR
Reuters	HIGH.DE
WKN	A3DSV0
ISIN	DE000A3DSV01

Key shareholders

Management & Founders	71.6%
Other institutional investors	12.7%
Free Float	15.7%

Estimates changes

	2023e	2024e	2025e
Sales	0%	2%	2%
EBIT	0%	1%	1%
EPS	0%	1%	1%

Comment on changes

- We model slight incremental revenues from telecan° from 2024e onwards.

Guidance

- 2023 sales: High double-digit percentage growth
- 2023 EBITDA: At least break-even

Financials

Profit and loss (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	0.5	5.2	14.2	30.7	57.1	72.6
Sales growth	n.a.	884.2%	171.7%	116.8%	85.7%	27.2%
Cost of sales	0.4	3.4	10.6	20.8	36.6	44.9
Gross profit	0.1	1.8	3.6	9.9	20.5	27.7
Sales and marketing	0.0	0.0	0.0	0.0	0.3	0.4
General and administration	0.3	0.9	3.3	6.5	11.7	14.5
Research and development	0.0	0.0	0.7	1.5	2.9	3.6
Other operating income	0.0	0.0	0.1	0.2	0.3	0.4
Other operating expenses	0.3	1.7	1.7	1.4	2.3	2.5
Total operating expenses	0.7	2.7	5.6	9.3	16.8	20.7
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	-0.6	-0.8	-2.0	0.6	3.6	7.0
Depreciation	0.0	0.1	0.3	0.5	0.9	1.1
EBITA	-0.6	-1.0	-2.3	0.2	2.8	5.9
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	-0.6	-1.0	-2.3	0.2	2.8	5.9
Interest income	0.0	0.0	0.0	0.0	0.0	0.0
Interest expenses	0.0	0.0	0.0	0.0	0.0	0.0
Investment income	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	0.0	0.0	0.0	0.0	0.0	0.0
Recurring pretax income from continuing operations	-0.6	-1.0	-2.3	0.2	2.8	5.9
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	-0.6	-1.0	-2.3	0.2	2.8	5.9
Income tax expense	0.0	0.0	0.0	0.0	0.8	1.8
Net income from continuing operations	-0.6	-1.0	-2.3	0.2	1.9	4.1
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0
Net income	-0.6	-1.0	-2.3	0.2	1.9	4.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0
Net profit (reported)	-0.6	-1.0	-2.3	0.2	1.9	4.1
Average number of shares	0.0	0.0	12.5	12.5	12.5	12.5
EPS reported	n.a.	n.a.	-0.18	0.01	0.16	0.33

Profit and loss (common size)	2020	2021	2022	2023e	2024e	2025e
Sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Cost of sales	80.9%	64.9%	74.6%	67.7%	64.2%	61.9%
Gross profit	19.1%	35.1%	25.4%	32.3%	35.8%	38.1%
Sales and marketing	0.0%	0.0%	0.0%	0.0%	0.5%	0.5%
General and administration	64.7%	18.2%	23.0%	21.3%	20.5%	20.0%
Research and development	0.0%	0.0%	5.0%	5.0%	5.0%	5.0%
Other operating income	0.0%	0.0%	0.5%	0.5%	0.5%	0.5%
Other operating expenses	59.1%	32.8%	12.0%	4.5%	4.0%	3.5%
Total operating expenses	123.8%	50.9%	39.5%	30.3%	29.5%	28.5%
EBITDA	-104.7%	-15.8%	-14.1%	2.1%	6.3%	9.6%
Depreciation	6.0%	2.8%	2.0%	1.5%	1.5%	1.5%
EBITA	-110.8%	-18.6%	-16.1%	0.6%	4.8%	8.1%
Amortisation of goodwill	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Amortisation of intangible assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Impairment charges	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBIT (inc revaluation net)	-110.8%	-18.6%	-16.1%	0.6%	4.8%	8.1%
Interest income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest expenses	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Investment income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Financial result	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Recurring pretax income from continuing operations	-110.8%	-18.6%	-16.1%	0.6%	4.8%	8.1%
Extraordinary income/loss	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings before taxes	-110.8%	-18.6%	-16.1%	0.6%	4.8%	8.1%
Tax rate	0.0%	0.0%	0.0%	0.0%	30.0%	30.0%
Net income from continuing operations	-110.8%	-18.6%	-16.1%	0.6%	3.4%	5.7%
Net income	-110.8%	-18.6%	-16.1%	0.6%	3.4%	5.7%
Minority interest	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net profit (reported)	-110.8%	-18.6%	-16.1%	0.6%	3.4%	5.7%

Source: Company data, NuWays

Balance sheet (EUR m)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	0.1	8.3	8.3	8.3	8.3	8.3
Property, plant and equipment	0.1	0.4	2.2	4.1	6.1	7.9
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0
FIXED ASSETS	0.2	8.7	10.5	12.3	14.3	16.2
Inventories	0.5	1.1	1.8	2.6	4.8	6.0
Accounts receivable	0.1	1.3	1.9	2.5	4.7	6.0
Other assets and short-term financial assets	0.0	0.0	0.0	0.0	0.0	0.0
Liquid assets	1.0	2.1	2.2	2.1	2.7	5.5
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0
Deferred charges and prepaid expenses	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	1.6	4.5	5.9	7.2	12.2	17.5
TOTAL ASSETS	1.8	13.1	16.4	19.6	26.5	33.7
SHAREHOLDERS EQUITY	1.6	11.9	13.0	13.2	15.1	19.2
MINORITY INTEREST	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0
Other provisions and accrued liabilities	0.0	0.2	0.2	0.2	0.2	0.2
Short-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	0.1	0.7	2.9	5.9	10.9	13.9
Advance payments received on orders	0.0	0.2	0.2	0.2	0.2	0.2
Other liabilities (incl. from lease and rental contracts)	0.0	0.0	0.0	0.0	0.0	0.0
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	0.1	0.9	3.1	6.1	11.1	14.1
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	1.8	13.1	16.4	19.6	26.5	33.7
Balance sheet (common size)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	7.3%	63.2%	50.5%	42.3%	31.2%	24.6%
Property, plant and equipment	3.8%	2.8%	13.5%	20.8%	22.8%	23.4%
Financial assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FIXED ASSETS	11.1%	66.0%	64.0%	63.1%	54.0%	48.0%
Inventories	25.8%	8.2%	10.8%	13.1%	17.9%	18.0%
Accounts receivable	8.2%	9.8%	11.8%	12.9%	17.7%	17.7%
Other assets and short-term financial assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Liquid assets	54.8%	15.9%	13.3%	10.8%	10.4%	16.3%
Deferred taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred charges and prepaid expenses	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%
CURRENT ASSETS	88.9%	34.0%	36.0%	36.9%	46.0%	52.0%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	90.7%	90.6%	79.1%	67.2%	56.8%	57.1%
MINORITY INTEREST	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Provisions for pensions and similar obligations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other provisions and accrued liabilities	0.2%	1.4%	1.1%	0.9%	0.7%	0.5%
Short-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts payable	7.4%	5.5%	17.8%	30.1%	41.2%	41.4%
Advance payments received on orders	0.0%	1.2%	0.9%	0.8%	0.6%	0.5%
Other liabilities (incl. from lease and rental contracts)	1.0%	0.3%	0.2%	0.2%	0.1%	0.1%
Deferred taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT LIABILITIES	8.4%	6.9%	18.9%	31.1%	41.9%	41.9%
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company data, NuWays

Cash flow statement (EUR m)	2020	2021	2022	2023e	2024e	2025e
Net profit/loss	-0.6	-1.0	-2.3	0.2	1.9	4.1
Depreciation of fixed assets (incl. leases)	0.0	0.1	0.3	0.5	0.9	1.1
Amortisation of goodwill & intangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from operating activities	-1.0	-1.7	-1.4	1.8	2.6	4.5
Increase/decrease in inventory	0.0	-0.6	-0.7	-0.8	-2.2	-1.3
Increase/decrease in accounts receivable	-0.6	-1.1	-0.7	-0.6	-2.2	-1.3
Increase/decrease in accounts payable	0.1	1.1	2.2	3.0	5.0	3.0
Increase/decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in working capital	-0.4	-0.7	0.8	1.6	0.7	0.4
Cash flow from operating activities	-1.0	-1.5	-1.2	2.2	3.5	5.6
CAPEX	0.2	0.5	2.1	2.3	2.9	2.9
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	-0.2	-0.5	-2.1	-2.3	-2.9	-2.9
Cash flow before financing	-1.2	-2.0	-3.3	-0.1	0.6	2.7
Increase/decrease in debt position	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	1.2	3.0	3.5	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	0.0	0.0	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	1.2	3.0	3.5	0.0	0.0	0.0
Increase/decrease in liquid assets	0.0	1.0	0.2	-0.1	0.6	2.7
Liquid assets at end of period	1.0	2.0	2.2	2.1	2.7	5.5

Key ratios (EUR m)	2020	2021	2022	2023e	2024e	2025e
P&L growth analysis						
Sales growth	n.a.	884.2%	171.7%	116.8%	85.7%	27.2%
EBITDA growth	n.a.	48.5%	143.3%	-177.8%	464.7%	93.3%
EBIT growth	n.a.	64.9%	136.4%	-118.6%	1433.6%	113.7%
EPS growth	n.a.	n.a.	n.a.	n.a.	973.5%	113.7%
Efficiency						
Sales per employee	70.7	289.8	566.9	787.9	1,201.3	2,902.3
EBITDA per employee	n.a.	n.a.	n.a.	16.4	76.2	280.0
No. employees (average)	8	18	25	39	48	25
Balance sheet analysis						
Avg. working capital / sales	89.0%	14.4%	3.9%	0.9%	-0.9%	-2.1%
Inventory turnover (sales/inventory)	1.2	4.8	8.0	12.0	12.0	12.0
Accounts receivable turnover	100.5	89.9	50.0	30.0	30.0	30.0
Accounts payable turnover	111.9	77.5	75.0	70.0	70.0	70.0
Cash flow analysis						
Free cash flow	-1.2	-2.0	-3.3	-0.1	0.6	2.7
Free cash flow/sales	-219.2%	-38.3%	-23.2%	-0.2%	1.1%	3.8%
FCF / net profit	198.0%	206.6%	143.6%	neg.	32.5%	66.0%
Capex / sales	30.2%	9.3%	15.0%	7.5%	5.0%	4.0%
Solvency						
Net debt	2.6	2.6	2.6	2.6	-2.7	-5.5
Net Debt/EBITDA	-4.7	-3.2	-1.3	4.1	0.0	0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Returns						
ROCE	-44.4%	-14.0%	-17.9%	1.3%	19.1%	33.8%
ROE	-36.5%	-8.2%	-17.6%	1.4%	12.8%	21.5%
Adjusted FCF yield	-0.5%	-0.8%	-1.1%	0.1%	1.6%	3.5%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	n.a.	n.a.	-0.18	0.01	0.16	0.33
Average number of shares	0.0	0.0	12.5	12.5	12.5	12.5
Valuation ratios						
P/BV	77.7	10.5	9.6	9.5	8.3	6.5
EV/sales	240.6	24.4	14.4	4.1	2.1	1.6
EV/EBITDA	-229.8	-154.8	-102.1	198.9	33.7	17.1
EV/EBIT	-217.2	-131.7	-89.4	707.2	44.2	20.2

Source: Company data, NuWays

Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
Cantourage Group SE	2,8

Historical target price and rating changes for Cantourage Group SE

Company	Date	Analyst	Rating	Target Price	Close
Cantourage Group SE	19.05.2023	Sandherr, Christian	Buy	EUR 12.00	EUR 9.91
	14.04.2023	Sandherr, Christian	Hold	EUR 12.00	EUR 10.04
	20.12.2022	Sandherr, Christian	Hold	EUR 18.00	EUR 15.80

1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjustment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under:

Date of publication creation: 06/09/2023 08:05 AM

Date of publication dissemination: 06/09/2023 08:05 AM

Contacts

NuWays AG

Mittelweg 16-17
20148 Hamburg
Germany

info@nuways-ag.com
www.nuways-ag.com



Christian Sandherr

Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow

Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Vaishnavi Khare

Analyst

vaishnavi.khare@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com

Find us on Social Media

Instagram



Twitter



LinkedIn

